子宫切除术后新发持续性阿片类药物使用的定义开发与患病率
本研究利用Optum Clinformatics数据库2011年1月1日至2014年12月31日子宫切除术数据,在24,331例阿片类药物初治女性中确定新发持续性阿片类药物使用的数据驱动定义:术后6个月内≥2次阿片类药物处方配药且每3个月≥1次,并且总口服吗啡当量≥1150或供药天数≥39。患病率为0.5%(n=122)。独立相关因素包括年龄增加、非裔美国人种族、妇科恶性肿瘤、经腹途径、抑郁/焦虑和术前阿片类药物处方。
要点
- 新发持续性阿片类药物使用定义:术后6个月内≥2次配药且每3个月≥1次,并且总口服吗啡当量≥1150或供药天数≥39。
- 阿片类药物初治子宫切除女性中新发持续性阿片类药物使用患病率为0.5%(n=122)。
- 术前阿片类药物处方和经腹手术途径是两个可能可干预的危险因素。
核心结论
- 基于本定义,阿片类药物初治子宫切除女性中新发持续性阿片类药物使用患病率低;但术前阿片类药物处方和经腹手术途径是两个可能可干预的危险因素。
研究设计与样本
- 使用Optum Clinformatics数据库(单一全国性私人健康保险公司的医疗和药房数据),纳入2011年1月1日至2014年12月31日子宫切除术、年龄≤63岁、术前8个月(排除术前30天)无阿片类药物配药且术后6个月内无额外手术的阿片类药物初治女性,共24,331例。
主要发现
- 新发持续性阿片类药物使用定义为术后6个月内≥2次阿片类药物配药且每3个月≥1次,并且总口服吗啡当量≥1150或供药天数≥39;患病率为0.5%(n=122)。
- 新发持续使用组围手术期中位口服吗啡当量为437.5 mg(四分位距200-750),非持续使用组为225 mg(四分位距150-300),P<.0001。
- 独立相关因素包括:年龄增加(校正比值比1.04,95%置信区间1.01-1.06,P=.006)、非裔美国人种族(参照:白人,校正比值比1.61,95%置信区间1.02-2.55,P=.04)、妇科恶性肿瘤(校正比值比7.61,95%置信区间3.35-17.27,P<.0001)、经腹途径(校正比值比3.61,95%置信区间2.03-6.43,P<.0001)、抑郁/焦虑(校正比值比2.62,95%置信区间1.71-4.02,P<.0001)和术前阿片类药物配药(校正比值比2.76,95%置信区间1.87-4.07,P<.0001)。
- 模型C统计量为0.74。
关键数值与推荐
- 新发持续性阿片类药物使用定义:术后6个月内≥2次阿片类药物配药且每3个月≥1次,并且总口服吗啡当量≥1150或供药天数≥39。
- 患病率为0.5%(n=122)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioids used for postoperative pain control after surgery have been associated with an increased risk of chronic opioid use. Hysterectomy is the most common major gynecological procedure in the United States; however, we lack a data-driven definition of new persistent opioid use specific to hysterectomy. OBJECTIVE: The objectives of the study were as follows: (1) determine a data-driven definition of new persistent opioid use among opioid naïve women undergoing hysterectomy and (2) determine the prevalence of and risk factors for new persistent opioid use. STUDY DESIGN: We used data from Optum Clinformatics that include both medical and pharmacy data from a single national private health insurer. Hysterectomies performed from Jan. 1, 2011, to Dec. 31, 2014, were identified using current procedural terminology and International Classification of Diseases, ninth revision, codes. Inclusion criteria included the following: age ≤63 years at hysterectomy, no opioid fills for 8 months preceding (excluding the 30 days immediately prior), and no additional surgical procedures within 6 months after hysterectomy. The perioperative period was defined as 30 days prior to 14 days after hysterectomy. Number of opioid prescription fills, days supplied, and total oral morphine equivalents were analyzed to determine the distribution of opioid use in the perioperative and postoperative periods. We obtained demographics including age, race, educational level, and division of the country according to the US Census Bureau and used International Classification of Diseases, ninth revision, diagnosis codes to identify hysterectomy indications, surgical route, chronic pain disorders, depression/anxiety, and substance abuse. Bivariate analyses were used to compare persistent with nonpersistent opioid users. A hierarchical logistic regression model controlling for regional variation was used to determine factors associated with new persistent opioid use following hysterectomy. RESULTS: A total of 24,331 women were included in the analysis. New persistent opioid use was defined as follows: ≥2 opioid fills within 6 months of hysterectomy with ≥1 fill every 3 months and either total oral morphine equivalent ≥1150 or days supplied ≥39. Based on this definition, the prevalence of new persistent opioid use was 0.5% (n = 122). Median perioperative oral morphine equivalents prescribed to those who became new persistent users was 437.5 mg (interquartile range, 200-750) compared with 225 mg (interquartile range, 150-300) for nonpersistent users (P < .0001). Factors independently associated with new persistent opioid use included the following: increasing age (adjusted odds ratio, 1.04, 95% confidence interval, 1.01-1.06, P = .006), African-American race (reference: white, adjusted odds ratio, 1.61 95% confidence interval, 1.02-2.55, P = .04), gynecological malignancy (adjusted odds ratio, 7.61, 95% confidence interval, 3.35-17.27, P < .0001), abdominal route (adjusted odds ratio, 3.61, 95% confidence interval, 2.03-6.43, P < .0001), depression/anxiety (adjusted odds ratio, 2.62, 95% confidence interval, 1.71-4.02, P < .0001), and preoperative opioid fill (adjusted odds ratio, 2.76, 95% confidence interval, 1.87-4.07, P < .0001). The C-statistic for this model is 0.74. CONCLUSION: Based on our definition, the prevalence of new persistent opioid use among opioid-naïve women undergoing hysterectomy is low; however, 2 potentially modifiable risk factors are preoperative opioid prescription and abdominal route of surgery.
引用
- Swenson CW, Kamdar NS, Seiler K, et al. Definition development and prevalence of new persistent opioid use following hysterectomy. Am J Obstet Gynecol. 2018. PMID: 29928864. doi:10.1016/j.ajog.2018.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。